A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

Completed · Phase 4

Conditions studied: Secondary Hyperparathyroidism

In brief

Hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis patients. Hectorol (doxercalciferol capsules) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis patients with Stage 3 or Stage 4 chronic kidney disease. Hectorol (doxercalciferol injection) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. This protocol will determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting subject from Hectorol (doxercalciferol injection.) The study will enroll hemodialysis patients that have been controlled on intravenous Hectorol. the information gained from this study will be a useful guide for physicians in managing CKD Stage 5 patients for whom a change from intravenous to oral vitamin D administration is appropriate.

Key facts

Study ID

NCT00418600

Run by

Genzyme, a Sanofi Company

People needed

36

Starts

2006-11-01

Expected to finish

2007-08-01

Last updated by the study team

2015-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject must be receiving hemodialysis three times per week for a minimum of six months.
• The subject must have been receiving Hectorol Injection for a minimum of 3 months. The subject must have been on a stable dose regimen, three times per week administration for a minimum of four weeks.
• The central laboratory assessment must be within the following ranges: serum iPTH between 150-600 pg/mL, inclusive; corrected calcium < 10.0 mg/dL; phosphorus < 7.0 mg/dL.

You may not qualify if…

• In the opinion of the Investigator, the subject currently has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any other clinically significant, unstable medical condition.
• Abnormal liver function as measured by ALT/AST greater than two times the upper limit of normal (ULN).
• The subject currently has malabsorption, severe chronic diarrhea, or ileostomy.
• Any evidence of active malignancy except for basal cell carcinoma of the skin. A history of malignancy is not an exclusion.
• Current use of aluminum or magnesium based binders.

Where it is running

• Study site — Hot Springs, Arkansas, United States
• Study site — Downey, California, United States
• Study site — Tarzana, California, United States
• Study site — Atlanta, Georgia, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Houston, Texas, United States
• Study site — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.